Bank of America
TCON

Bank of America’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Bank of America’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$68 – 8411
2022
Q4 		$68 Buy
+2
New +$60 ﹤0.01% 7747
2022
Q1 		– Sell
-39
Closed -$2K – 8912
2021
Q4 		$2K Buy
39
+2
+5% +$128 ﹤0.01% 8017
2021
Q3 		$3K Buy
37
+30
+429% +$2.54K ﹤0.01% 7850
2021
Q2 		$1K Buy
+7
New +$968 ﹤0.01% 7666
2020
Q1 		– Sell
-56
Closed -$3K – 7344
2019
Q4 		$3K Buy
56
+43
+331% +$2.83K ﹤0.01% 6851
2019
Q3 		$1K Buy
13
+5
+63% +$513 ﹤0.01% 7159
2019
Q2 		$1K Buy
+8
New +$1.26K ﹤0.01% 7084
2017
Q4 		– Sell
-25
Closed -$16K – 7308
2017
Q3 		$16K Hold
25
– – ﹤0.01% 6378
2017
Q2 		$12K Hold
25
– – ﹤0.01% 6386
2017
Q1 		$19K Hold
25
– – ﹤0.01% 6335
2016
Q4 		$25K Sell
25
-2
-7% -$2.29K ﹤0.01% 6253
2016
Q3 		$36K Buy
27
+2
+8% +$2.25K ﹤0.01% 5868
2016
Q2 		$22K Hold
25
– – ﹤0.01% 6207
2016
Q1 		$35K Buy
+25
New +$35.6K ﹤0.01% 5919
2015
Q4 		– Sell
-134
Closed -$262K – 7522
2015
Q3 		$262K Buy
+134
New +$313K ﹤0.01% 5191

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's TCON Position: Q1 2023 in Review

Bank of America sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2023, closing a stake of 2 shares — an estimated $68 sold.

Bank of America first reported a position in TCON in Q3 2015 and held it in 15 quarters. The position peaked at $262K in Q3 2015. 32 funds tracked by Wall St. Rank hold TCON as of Q1 2023.

  • Bank of America reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Bank of America sold 2 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $68.
  • Bank of America first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q3 2015 and held it in 15 quarters.
  • Bank of America's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $262K in Q3 2015.
  • 32 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Bank of America's 13F filing for Q1 2023, filed 12 May 2023.